<DOC>
	<DOCNO>NCT00432172</DOCNO>
	<brief_summary>This open-label study include two substudies random distribution . First , sample primary tumor obtain analyzed immunohistochemical technique determine several markers.Depending expression marker , patient characterize group 1 ( Luminal A phenotype ) group 2 ( Basal phenotype ) random assignment perform standard experimental treatment .</brief_summary>
	<brief_title>Selective Neoadjuvant Treatment According Immunohistochemical Subtype HER2 Negative Breast Cancer Patients</brief_title>
	<detailed_description>Group 1 ( Luminal A ) : - Standard treatment : EC x 4 - &gt; Tx4 - Selective treatment : Postmenopausic patient : exemestane x 6 month ; Premenopausic Patients : goserelin x 6 month + exemestane x 6 month Group 2 ( Basal ) : - Standard treatment : EC x 4 - &gt; Tx4 - Selective treatment : EC x 4 - &gt; CDPT x 4</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Written inform consent . Breast cancer histological diagnosis . Negative HER2neu tumour ( define IHQ 0,1+ ) . No evidence suspicion metastatic disease . Age &gt; = 18 year old . Performance status ( Karnofsky index ) &gt; = 80 ( ECOG 0,1 ) . Adequate cardiac function ECG previous 12 week . Hematology : neutrophil &gt; = 1,5 x10^9/l ; platelet &gt; = 100 x10^9/l ; hemoglobin &gt; = 10 g/dl . Adequate hepatic function : total bilirubin &lt; = 1x upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5xUNL ; alkaline phosphatase &lt; = 2.5xUNL . Adequate renal function : creatinine &lt; = 1xUNL ; creatinine clearance &gt; = 60 ml/min . Patients able comply study treatment followup . Negative pregnancy test previous 14 day . HER2neu positive tumour ( define IHQ 3+ positive FISH ) . Prior systemic therapy breast cancer ( immunotherapy , hormonotherapy , chemotherapy ) . Prior treatment anthracyclines taxanes ( paclitaxel , docetaxel ) previous malignancy . Prior radiotherapy breast cancer . Bilateral invasive breast cancer . Pregnant lactating woman . Previous grade &gt; = 2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria [ NCI CTC ] ) . Other serious comorbidities : congestive heart failure unstable angina ; prior history myocardial infarction previous year ; uncontrolled hypertension ( HT ) ; high risk arrhythmias ; history significant neurological psychiatric disorder ; uncontrolled active infection ; active peptic ulcer ; unstable diabetes mellitus ; dyspnea rest ; chronic therapy oxygen . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumor curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . Chronic treatment corticosteroid . Contraindications administration corticosteroid . Concomitant treatment therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Her2neu negative breast cancer .</keyword>
	<keyword>Neoadjuvant treatment .</keyword>
</DOC>